Hierarchical mesosilicalite nanoformulation integrated with cisplatin exhibits target-specific efficient anticancer activity

Jermy, B. Rabindran; Acharya, Sadananda; Ravinayagam, Vijaya; Alghamdi, Hajer Saleh; Akhtar, Sultan; Basuwaidan, Rehab S.

doi:10.1007/s13204-018-0786-9

Cited by 11 publications

(8 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mixture was stirred overnight in an ice cooled dark environment and then filtered, washed, and dried at room temperature to obtain the final product. The Cp content determined to be 0.12 mmol/g of nanocarrier 4 .…”

Section: Methodsmentioning

confidence: 96%

“…Mesocellular foam (MSU-F) was purchased from Sigma Aldrich, while HYPS was purchased from Superior silica, USA. S-16 was synthesized based on our earlier reported literatures 4,17 . In brief, 6 g of F127 (Sigma) was dissolved in 290 g of H 2 O through stirring for 2 h. Then 12.6 g of 35 wt% HCl and 19.2 g of nBuOH was added at once and stirred for 1 h. Later, 29 g of TEOS (Aldrich, 98%) was added and again stirred at 40 °C for 24 h. The solution was hydrothermally heated at 100 °C for 24 h. Then the mixture cooled, filtered, washed and dried in air for 5 h, then dried at 100 °C overnight.…”

Section: Methodsmentioning

confidence: 99%

“…Similarly, a reverse multi-step microemulsion technique reported to increase the solubility of Cp source in the presence of potassium chloride 3 . Recently, we have shown that the hierarchical structured mesosilicalite capability to carry cisplatin 4 .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

SPIONs/3D SiSBA-16 based Multifunctional Nanoformulation for target specific cisplatin release in colon and cervical cancer cell lines

Jermy

Alomari

Ravinayagam

et al. 2019

Sci Rep

Self Cite

View full text Add to dashboard Cite

Multifunctional nanomaterials can be used for dual applications: drug delivery as well as in bioimaging. In current study, we investigated potential use of silica based supports; 3D cage type SiSBA-16 (S-16), monodispersed hydrophilic spherical silica (HYPS) and mesocellular foam (MSU-F) for cisplatin (Cp) delivery. To obtain magnetic resonance characteristics, 10 wt% iron oxide was loaded through enforced adsorption technique. For pH stimuli responsive release of Cp, 10 wt%SPIONs/S-16 was functionalized with 3-(Aminopropyl)triethoxysilane (A) and poly acrylic acid (PAA) termed as 10 wt%SPIONs/S-16-A-Cp and 10 wt%SPIONs/S-16-APAA-Cp. By TEM analysis, the average diameter of the SPIONs was found to range between 10–60 nm. VSM analysis showed saturation magnetization over S-16, HYPS and MSU-F were in the following order: 10 wt%SPIONs/HYPS (4.08 emug−1) > 10 wt%SPIONs /S-16 (2.39 emug−1) > 10 wt%SPIONs/MSU-F (0.23 emug−1). Cp release study using dialysis membrane in PBS solution over 10 wt%SPIONs/S-16 nanoformulations showed highest cumulative release (65%) than 10 wt%SPIONs/MSU-F-A-Cp (63%), 10 wt%SPIONs/HYPS-A-Cp (58%), and Cp-F127/S-16 (53%), respectively. 10 wt%SPIONs/S-16-A-Cp and 10 wt%SPIONs/S-16-APAA-Cp were evaluated for in vitro target anticancer efficiency in human cancer cell lines (colon cancer (HCT 116), cervical cancer (HeLa)) and normal cells (Human embryonic kidney cells (HEK293) using MTT and DAPI staining. 10 wt%SPIONs/S-16-A-Cp treated Hela and HCT116 cancerous cell lines showed significant control of cell growth, apoptotic activity and less cytotoxic effect as compared to Cp and 10 wt%SPIONs/S-16. Target specific Cp release in the cells shows that 10 wt%SPIONs/S-16-A-Cp can be easily upgraded for magnetic resonance imaging capability.

show abstract

Section: Methodsmentioning

confidence: 96%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

SPIONs/3D SiSBA-16 based Multifunctional Nanoformulation for target specific cisplatin release in colon and cervical cancer cell lines

Jermy

Alomari

Ravinayagam

et al. 2019

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…After stirring overnight, the solution mixture was filtered and washed with 15 mL of normal saline solution. Then the adsorbed cisplatin was calculated using UV–visible spectroscopy at 208 nm [14]. Depending on the support, the loaded formulations were labelled as CuFe 2 O 4 /HYPS, CuFe 2 O 4 /AlMSU-F and CuFe 2 O 4 /silicalite.…”

Section: Methodsmentioning

confidence: 99%

Targeted therapeutic effect against the breast cancer cell line MCF-7 with a CuFe₂O₄/silica/cisplatin nanocomposite formulation

Jermy¹,

Ravinayagam²,

Alamoudi³

et al. 2019

Beilstein J. Nanotechnol.

Self Cite

View full text Add to dashboard Cite

The combination of magnetic nanoparticles with a porous silica is a composite that has attracted significant attention for potential multifunctional theranostic applications. In this study, 30 wt % CuFe2O4 was impregnated into a matrix of monodispersed spherical hydrophilic silica (HYPS) nanoparticles through a simple dry impregnation technique. The chemotherapy drug cisplatin was loaded through electrostatic equilibrium adsorption over 24 h in normal saline solution. The presence of cubic spinel CuFe2O4 on HYPS was confirmed through powder X-ray diffraction (PXRD), Fourier transform infrared spectroscopy (FTIR) and diffuse reflectance UV–vis spectroscopy (DR UV–vis) analysis. The HYPS particles showed a surface area of 170 m2/g, pore size of 8.3 nm and pore volume of 0.35 cm3/g. The cisplatin/CuFe2O4/HYPS nanoformulation showed the accumulation of copper ferrite nanoparticles on the surface and in the pores of HYPS with a surface area of 45 m2/g, pore size of 16 nm and pore volume of 0.18 cm3/g. Transmission electron microscopy (TEM) and energy dispersive X-ray (EDX) mapping analysis showed the presence of homogeneous silica particles with nanoclusters of copper ferrite distributed on the HYPS support. Vibrating sample magnetometry (VSM) analysis of CuFe2O4/HYPS showed paramagnetic behavior with a saturated magnetization value of 7.65 emu/g. DRS UV–vis analysis revealed the functionalization of cisplatin in tetrahedral and octahedral coordination in the CuFe2O4/HYPS composite. Compared to other supports such as mesocellular foam and silicalite, the release of cisplatin using the dialysis membrane technique was found to be superior when CuFe2O4/HYPS was applied as the support. An in vitro experiment was conducted to determine the potential of CuFe2O4/HYPS as an anticancer agent against the human breast cancer cell line MCF-7. The results show that the nanoparticle formulation can effectively target cancerous cells and could be an effective tumor imaging guide and drug delivery system.

show abstract

“…The solution mixture was then filtered using what paper in glass funnel and then vacum dried for 3 h to produce Fe/S-16-A. Cisplatin loading was carried out by dissolving 30 mg of Cp with 600 mg of Fe/S-16-AP in normal saline solution (NSS) following our previously published literature to produce Fe/S-16-A-Cp [10]. The cisplatin content determined to be 0.12 mmol/g of the nanocarrier.…”

Section: Methodsmentioning

confidence: 99%

Cisplatin-functionalized three-dimensional magnetic SBA-16 for treating breast cancer cells (MCF-7)

Alomari

Jermy

Ravinayagam

et al. 2019

Artificial Cells, Nanomedicine, and Biotechnology

Self Cite

View full text Add to dashboard Cite

The engineering of multifunctional therapeutics in an integrated single platform is demonstrated using three-dimensional . 10 wt% iron oxide nanoparticles (Fe) were loaded into the cage type of cubic pores through enforced adsorption technique. Fe/S-16 is then functionalized with amine-based silane (A), polyacrylic acid (P) and cisplatin (Cp). The physicochemical textural analysis showed the formation of nano metal oxide distributions at pore walls of S-16 with magnetization of 2.39 emu/g. S-16 based nanoformulations showed high percentage of Cp adsorption (90%) and percentage cumulative release (60%). in vitro study of Fe/S-16-A-Cp showed high toxicity against breast cancer cell line MCF-7 and normal cell line Human foreskin fibroblast (HFF-1) compared to Fe/S-16 indicating cisplatin profusion inside the cells than free cisplatin. While skin fibroblast seems to be resistant to Fe/S-16-AP-Cp with very high LC 50 in compare to MCF-7. This indicates the unrelease of cisplatin in skin fibroblast after Fe/S-16-AP-Cp treatment due to effective encapsulation inside the cubic pores and core blockage due to pH-sensitive polyacrylic acid. Also, these treatments resulted in morphological changes in the cells such as DNA condensation and nuclear fragmentation. ARTICLE HISTORY

show abstract

Hierarchical mesosilicalite nanoformulation integrated with cisplatin exhibits target-specific efficient anticancer activity

Cited by 11 publications

References 39 publications

SPIONs/3D SiSBA-16 based Multifunctional Nanoformulation for target specific cisplatin release in colon and cervical cancer cell lines

SPIONs/3D SiSBA-16 based Multifunctional Nanoformulation for target specific cisplatin release in colon and cervical cancer cell lines

Targeted therapeutic effect against the breast cancer cell line MCF-7 with a CuFe₂O₄/silica/cisplatin nanocomposite formulation

Cisplatin-functionalized three-dimensional magnetic SBA-16 for treating breast cancer cells (MCF-7)

Contact Info

Product

Resources

About

Hierarchical mesosilicalite nanoformulation integrated with cisplatin exhibits target-specific efficient anticancer activity

Cited by 11 publications

References 39 publications

SPIONs/3D SiSBA-16 based Multifunctional Nanoformulation for target specific cisplatin release in colon and cervical cancer cell lines

SPIONs/3D SiSBA-16 based Multifunctional Nanoformulation for target specific cisplatin release in colon and cervical cancer cell lines

Targeted therapeutic effect against the breast cancer cell line MCF-7 with a CuFe2O4/silica/cisplatin nanocomposite formulation

Cisplatin-functionalized three-dimensional magnetic SBA-16 for treating breast cancer cells (MCF-7)

Contact Info

Product

Resources

About

Targeted therapeutic effect against the breast cancer cell line MCF-7 with a CuFe₂O₄/silica/cisplatin nanocomposite formulation